Kelekci 2006.

Methods	Patients were randomised to one of four treatment groups by a series of computer‐generated random numbers.
Participants	178 pregnant women (group I: 93, group II: 85) Inclusion criteria: genetic indications, 13‐24 weeks gestation. Exclusion criteria: previous uterine scar, pulmonary, hepatic, renal or cardiovascular disease, intrauterine death, vaginal bleeding, uterine contractions, any signs of cervical dilatation, a Bishop score of 4, vaginal infection, a discrepancy of 2 weeks between the gestational age determined by last menstrual period and ultrasonographic gestational age
Interventions	Group I: 200 μg misoprostol, vaginally, followed by 100 μg of oral misoprostol every 4 hour for 24 hrs. Group II: extra‐amniotic ethacridine lactate, 10 ml instilled per gestational week, to a maximum of 200 ml. Group III: combination of misoprostol and oxytocin. 200 μg misoprostol, vaginally, followed by 100 μg of oral misoprostol every 4 hour for 24 hrs. An initial dose of 6 mU/min oxytocin was given, followed by additional 6 mU/min doses every 20 min. Group IV: combination of ethacridine lactate and oxytocin. Ethacridine lactate was given extra‐amniotic, 10 ml instilled per gestational week, to a maximum of 200 ml. Oxytocin was administered in a similar way as in group III. For analyses, we did not include group III and IV.
Outcomes	Time to induce abortion, success/failure rates, side‐effects and complications.
Notes	Definition of abortion: complete evacuation of fetal and placental tissues within 24 h of the initiation of medical abortion. 14 cases of endometritis and 20 cases of incomplete abortions were described.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	B ‐unclear
Blinding? All outcomes	High risk
Free of other bias?	Low risk	No statistically significant differences between the groups in terms of maternal age, gestational age and parity.